Table 2.

First observed platinum-based treatment (before index treatment)

Observed agents/procedures	N (%) patients (N = 201)
Paclitaxel	109 (54.3%)
Carboplatin	104 (51.7%)
Noncomplex chemotherapy (inpatient)	82 (40.8%)
Moderate complex chemotherapy (inpatient)	42 (20.9%)
Doxorubicina	14 (7.0%)
Bevacizumab	13 (6.5%)
Cisplatin	11 (5.5%)
23 other agents/procedures (< 10 patients)	37 (18.4%)
Observed regimen
Carboplatin and paclitaxel (and combinations)
Inpatient procedures
Other carboplatin combinations
Cisplatin combinations
Oxaliplatin combination

^aDoxorubicin and liposomal doxorubicin data were captured separately but were not distinguished between in these analyses